Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Guaifenesin
Accession Number
DB00874  (APRD01005)
Type
Small Molecule
Groups
Approved, Investigational, Vet approved
Description

Guaifenesin possesses a storied history, having been originally formally approved by the US FDA in 1952 and continues to be one of very few - if not perhaps the only drug that is readily available and used as an expectorant 11. Since that time the agent has been a combination component of various prescription and non-prescription over-the-counter cough and cold products and is currently a widely available over-the-counter generic medication 11. Although it is principally believed that guaifenesin elicits an action to facilitate productive cough to manage chest congestion 4,7,9,10,11, it is not known whether the agent can reliably mitigate coughing.

Regardless, on March 1, 2007, the FDA received a petition asking the FDA to notify the public that some antitussives, expectorants, decongestants, antihistamines, and cough/cold combinations are not known to be safe and effective in children under the age of 6 years 11. After the negotiation between FDA and major manufacturers, a voluntary transition of labels for not using guaifenesin in children under the age of 4 years was endorsed by FDA in 2008 11.

Furthermore, there has also been contemporary research to suggest that guaifenesin possesses and is capable of demonstrating anticonvulsant and muscle relaxant effects to some degree possibly by acting as an NMDA receptor antagonist 3.

Structure
Thumb
Synonyms
  • Glyceryl guaiacolate
  • Guaifenesin
  • Guaifenesina
  • guaiphenesin
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
GuaifenesinTablet1200 mg/1OralPrasco, Laboratories2010-12-012011-01-20Us
GuaifenesinTablet1000 mg/1OralPrasco, Laboratories2010-12-012011-01-20Us
GuaifenesinTablet600 mg/1OralPrasco, Laboratories2010-12-012011-01-20Us
GuaifenesinTablet200 mg/1OralContract Pharmacy Services Pa2010-10-06Not applicableUs
Guaifenesin NrLiquid100 mg/5mLOralSilarx Pharmaceuticals, Inc.2000-02-012011-02-04Us
Organidin NRTablet200 mg/1OralMeda Pharmaceuticals Ltd1995-09-012013-08-31Us
Organidin NRLiquid100 mg/5mLOralMeda Pharmaceuticals Ltd1995-09-012010-09-30Us
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
7 Select Mucus ReliefTablet, extended release600 mg/1Oral7 Eleven2014-10-262017-06-07Us
Adult TussinSyrup100 mg/5mLOralRite Aid2013-09-212015-10-15Us
Adult Tussin Chest CongestionSolution200 mg/10mLOralHYVEE INC1997-06-252019-08-05Us
Air PowerTablet200 mg/1OralSchwabe North America, Inc2003-05-19Not applicableUs
Air-powerTabletOralEnzymatic Therapy, Inc.1997-03-202002-08-08Canada
AkinSolution100 mg/5mLOralSouthern Sales & Service, Inc.2015-01-01Not applicableUs
AuroMucus - Childrens Chest CongestionSolution100 mg/5mLOralAurohealth LLC2015-08-24Not applicableUs
Aurotussin Mucus plus Chest Congestion (ORIGINAL)Liquid200 mg/10mLOralAurohealth LLC2015-06-26Not applicableUs
Balminil ExpectorantSyrupOralTEVA Canada Limited1979-12-31Not applicableCanada
Balminil Expectorant (sucrose Free)SyrupOralTEVA Canada Limited1979-12-31Not applicableCanada
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
7 Select Maximum StrengthGuaifenesin (400 mg/20mL) + Dextromethorphan hydrobromide monohydrate (20 mg/20mL)SolutionOral7-Eleven2019-03-25Not applicableUs
7 select Tussin DMGuaifenesin (200 mg/10mL) + Dextromethorphan hydrobromide monohydrate (20 mg/10mL)SolutionOral7-Eleven2016-05-312021-06-30Us
Acetaminophen 500mg, Dextromethorphan HBr 10mg, Guaifenesin 200mg, Phenylephrine HCl 5mgGuaifenesin (200 mg/1) + Acetaminophen (325 mg/1) + Dextromethorphan hydrobromide monohydrate (10 mg/1) + Phenylephrine hydrochloride (5 mg/1)TabletOralStrive Pharmaceuticals Inc2018-12-20Not applicableUs
Acetaminophen, Dextromethorphan Hydrobromide, Guaifenesin, Phenylephrine HydrochlorideGuaifenesin (200 mg/1) + Acetaminophen (325 mg/1) + Dextromethorphan hydrobromide monohydrate (10 mg/1) + Phenylephrine hydrochloride (5 mg/1)Tablet, coatedOralAAA Pharmaceutical, Inc.2012-12-28Not applicableUs
Acetaminophen, Dextromethorphan Hydrobromide, Guaifenesin, Phenylephrine HydrochlorideGuaifenesin (200 mg/1) + Acetaminophen (325 mg/1) + Dextromethorphan hydrobromide monohydrate (10 mg/1) + Phenylephrine hydrochloride (5 mg/1)Tablet, coatedOralAAA Pharmaceutical, Inc.2012-12-28Not applicableUs
Acetaminophen, Dextromethorphan Hydrobromide, Guaifenesin, Phenylephrine HydrochlorideGuaifenesin (100 mg/1) + Acetaminophen (325 mg/1) + Dextromethorphan hydrobromide monohydrate (10 mg/1) + Phenylephrine hydrochloride (5 mg/1)Tablet, coatedOralAAA Pharmaceutical, Inc.2012-12-22Not applicableUs
Acetaminophen, Dextromethorphan Hydrobromide, Guaifenesin, Phenylephrine HydrochlorideGuaifenesin (200 mg/1) + Acetaminophen (325 mg/1) + Dextromethorphan hydrobromide monohydrate (10 mg/1) + Phenylephrine hydrochloride (5 mg/1)Tablet, coatedOralAAA Pharmaceutical, Inc.2012-08-02Not applicableUs
Actidom DmxGuaifenesin (200 mg/5mL) + Dextromethorphan hydrobromide monohydrate (30 mg/5mL) + Phenylephrine hydrochloride (10 mg/5mL)SolutionOralActipharma, Inc2015-08-13Not applicableUs
ActinelGuaifenesin (200 mg/5mL) + Dextromethorphan hydrobromide monohydrate (15 mg/5mL) + Pseudoephedrine hydrochloride (30 mg/5mL)SolutionOralActipharma, Inc2014-09-24Not applicableUs
Actinel DMGuaifenesin (400 mg/5mL) + Dextromethorphan hydrobromide monohydrate (20 mg/5mL) + Phenylephrine hydrochloride (10 mg/5mL)SolutionOralActipharma, Inc2019-05-20Not applicableUs
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
A-Tan 12X SuspensionGuaifenesin (100 mg/5mL) + Mepyramine tannate (30 mg/5mL) + Phenylephrine tannate (5 mg/5mL)SuspensionOralAmneal Pharmaceuticals2006-01-062008-12-05Us
Bromhist PDXGuaifenesin (50 mg/5mL) + Brompheniramine maleate (2 mg/5mL) + Dextromethorphan hydrobromide monohydrate (5 mg/5mL) + Phenylephrine hydrochloride (5 mg/5mL)SyrupOralCypress Pharmaceutical, Inc2006-04-282011-08-26Us
BrontussGuaifenesin (400 mg/1) + Dextromethorphan hydrobromide monohydrate (20 mg/1)TabletOralPortal Pharmaceuticals2010-05-032012-05-31Us
CarbatussGuaifenesin (100 mg/5mL) + Pentoxyverine citrate (20 mg/5mL) + Phenylephrine hydrochloride (10 mg/5mL)LiquidOralGm Pharmaceuticals2000-11-012007-11-01Us
CarbetaplexGuaifenesin (100 mg/5mL) + Pentoxyverine citrate (20 mg/5mL) + Phenylephrine hydrochloride (15 mg/5mL)LiquidOralBreckenridge Pharmaceutical, Inc.2004-04-012009-09-30Us51991 08320180906 25352 173omie
Codeine Phosphate GuaifenesinGuaifenesin (200 mg/5mL) + Codeine phosphate hemihydrate (10 mg/5mL)LiquidOralKylemore Pharmaceuticals, LLC2010-01-012012-11-30Us
CrantexGuaifenesin (100 mg/5mL) + Phenylephrine hydrochloride (7.5 mg/5mL)LiquidOralBreckenridge Pharmaceutical, Inc.2002-02-012011-09-30Us
CrantexGuaifenesin (100 mg/5mL) + Phenylephrine hydrochloride (7.5 mg/5mL)LiquidOralPhysicians Total Care, Inc.2004-03-172011-06-30Us
Dilex-G 400Guaifenesin (400 mg/1) + Dyphylline (200 mg/1)TabletOralPoly Pharmaceuticals2006-09-082011-09-30Us
Donatuss DCGuaifenesin (50 mg/5mL) + Dihydrocodeine bitartrate (7.5 mg/5mL) + Phenylephrine hydrochloride (7.5 mg/5mL)SyrupOralLaser Pharmaceuticals Llc2009-10-072013-09-30Us
International/Other Brands
Duratuss G / Ganidin (Cypress) / Hustosil (Kyoto Yakuhin) / Hytuss (Hyrex) / Robitussin (Wyeth) / Scot-tussin Expectorant / Sinumist-SR
Categories
UNII
495W7451VQ
CAS number
93-14-1
Weight
Average: 198.2158
Monoisotopic: 198.089208936
Chemical Formula
C10H14O4
InChI Key
HSRJKNPTNIJEKV-UHFFFAOYSA-N
InChI
InChI=1S/C10H14O4/c1-13-9-4-2-3-5-10(9)14-7-8(12)6-11/h2-5,8,11-12H,6-7H2,1H3
IUPAC Name
3-(2-methoxyphenoxy)propane-1,2-diol
SMILES
COC1=CC=CC=C1OCC(O)CO

Pharmacology

Indication

Guaifenesin is an expectorant that is indicated for providing temporary symptomatic relief from congested chests and coughs which may be due to a cold, bronchitis, and/or other breathing illnesses Label,8,6.

Associated Conditions
Pharmacodynamics

Guaifenesin is categorized as an expectorant that acts by enhancing the output of phlegm (sputum) and bronchial secretions via decreasing the adhesiveness and surface tension of such material 9. Furthermore, guaifenesin elicits an increased flow of less viscous gastric secretions that subsequently promote ciliary action - all actions that ultimately change dry, unproductive coughing to coughs that are more productive and less frequent 9. Essentially, by decreasing the viscosity and adhesiveness of such secretions, guaifenesin enhances the efficacy of mucociliary activity in removing accumulated secretions from the upper and lower airway 9.

Mechanism of action

Although the exact mechanism of action of guaifenesin may not yet be formally or totally elucidated, it is believed that expectorants like guaifenesin function by increasing mucus secretion 4. Moreover, it is also further proposed that such expectorants may also act as an irritant to gastric vagal receptors, and recruit efferent parasympathetic reflexes that can elicit glandular exocytosis that is comprised of a less viscous mucus mixture 4. Subsequently, these actions may provoke coughing that can ultimately flush difficult to access, congealed mucopurulent material from obstructed small airways to facilitate a temporary improvement for the individual 4.

Consequently, while it is generally proposed that guaifenesin functions as an expectorant by helping to loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive, there has also been research to suggest that guaifenesin possesses and is capable of demonstrating anticonvulsant and muscle relaxant effects to some degree possibly by acting as an NMDA receptor antagonist 3.

TargetActionsOrganism
UNMDA receptor
antagonist
Humans
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption

Studies have shown that guaifenesin is well absorbed from and along the gastrointestinal tract after oral administration 2,10,7.

Volume of distribution

The geometric mean apparent volume of distribution of guaifenesin determined in healthy adult subjects is 116L (CV=45.7%) 11.

Protein binding

Information regarding the protein binding of guaifenesin is not readily available or accessible.

Metabolism

After the oral administration of 400 mg guaifenesin, the agent experiences rapid hydrolysis (more than 60% of the dose hydrolyzed over a range of seven hours) with β-(2-methoxyphenoxy)-lactic acid found as the major urinary metabolite but no parent drug detectable in the urine 5,7. Moreover, it has been observed that guaifenesin also experiences both oxidation and demethylation 5. In particular, the medication is quickly metabolized hepatically by way of oxidation to β-(2-methoxyphenoxy)-lactic acid 5. Furthermore, guaifenesin is also demethylated by O-demethylase in liver microsomes to the point where about 40% of an administered dose is excreted as this metabolite in the urine within 3 hours 5. In fact, O-demethylase appears to be the primary enzyme for the metabolism of guaifenesin and the primary metabolites of the substance are β-(2-methoxyphenoxy)-lactic acid and the demethylated hydroxyguaifenesin, both of which are themselves inactive moieties 5.

Route of elimination

After administration, guaifenesin is metabolized and then largely excreted in the urine 5,6,7,10,11.

Half life

The half-life in plasma observed for guaifenesin is approximately one hour 5,6,7,10,11.

Clearance

The mean clearance recorded for guaifenesin is about 94.8 L/hr (CV=51.4%) 11.

Toxicity

The most prevalent signs and symptoms associated with an overdose of guaifenesin have been nausea and vomiting 7.

Although adequate and well-controlled studies in pregnant women have not been performed, the Collaborative Perinatal Project monitored 197 mother-child pairs exposed to guaifenesin during the first trimester 7. An increased occurrence of inguinal hernias was found in the neonates 7. However, congenital defects were not strongly associated with guaifenesin use during pregnancy in 2 large groups of mother-child pairs 7.

Moreover, guaifenesin is excreted in breast milk in small quantities 7. Subsequently, caution should be exercised by balancing the potential benefit of treatment against any possible risks 7.

Additionally, an LD50 value of 1510 mg/kg (rat, oral) has been reported for guaifenesin MSDS.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
  • Take with a full glass of water.
  • Take without regard to meals.

References

Synthesis Reference

Wilfred P. Shum, Harry Mazurek, Jian Chen, "Process for producing enantiomerically enriched guaifenesin." U.S. Patent US5495052, issued August, 1949.

US5495052
General References
  1. Thompson GA, Solomon G, Albrecht HH, Reitberg DP, Guenin E: Guaifenesin Pharmacokinetics Following Single-Dose Oral Administration in Children Aged 2 to 17 Years. J Clin Pharmacol. 2016 Jul;56(7):894-901. doi: 10.1002/jcph.682. Epub 2016 Jan 24. [PubMed:26632082]
  2. Kagan L, Lavy E, Hoffman A: Effect of mode of administration on guaifenesin pharmacokinetics and expectorant action in the rat model. Pulm Pharmacol Ther. 2009 Jun;22(3):260-5. doi: 10.1016/j.pupt.2008.12.020. Epub 2009 Jan 6. [PubMed:19166957]
  3. Keshavarz M, Showraki A, Emamghoreishi M: Anticonvulsant Effect of Guaifenesin against Pentylenetetrazol-Induced Seizure in Mice. Iran J Med Sci. 2013 Jun;38(2):116-21. [PubMed:23825891]
  4. Yuta A, Baraniuk JN: Therapeutic approaches to mucus hypersecretion. Curr Allergy Asthma Rep. 2005 May;5(3):243-51. [PubMed:15842963]
  5. Albrecht HH, Dicpinigaitis PV, Guenin EP: Role of guaifenesin in the management of chronic bronchitis and upper respiratory tract infections. Multidiscip Respir Med. 2017 Dec 11;12:31. doi: 10.1186/s40248-017-0113-4. eCollection 2017. [PubMed:29238574]
  6. MyHealth.Alberta.ca Network: Guaifenesin - Oral Profile [Link]
  7. Electronic Medicines Compendium: Robitussin Chesty Cough Medicine Monograph [Link]
  8. Australian Government Department of Health Therapeutic Goods Administration OTC Medicines Monograph: Guaifenesin [File]
  9. A NOVEL STABILITY INDICATING HPLC METHOD FOR SIMULTANEOUS ESTIMATION OF GUAIPHENESIN, CHLORPHENERAMINE MALEATE & DEXTROMETHORPHAN HBr [File]
  10. National Pharmaceutical Regulatory Agency (NPRA) Guaiphenesin Product Information [File]
  11. CENTER FOR DRUG EVALUATION AND RESEARCH: CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS REVIEW(S) OF GUAIFENESIN/HYDROCODONE BITARTRATE [File]
External Links
Human Metabolome Database
HMDB0004998
KEGG Drug
D00337
PubChem Compound
3516
PubChem Substance
46508004
ChemSpider
3396
ChEBI
5551
ChEMBL
CHEMBL980
PharmGKB
PA449818
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Guaifenesin
ATC Codes
R05CA03 — Guaifenesin
AHFS Codes
  • 48:16.00 — Expectorants
FDA label
Download (394 KB)
MSDS
Download (73.4 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1CompletedBasic ScienceHealthy Volunteers6
1CompletedBasic ScienceHealthy Volunteers / Pharmocokinetics of Guaifenesin in Adults and Adolescents1
1CompletedOtherBioequivalence / Healthy Volunteers1
1CompletedSupportive CareHealthy Volunteers1
1CompletedTreatmentCoughing2
1CompletedTreatmentHealthy Volunteers1
1CompletedTreatmentMucociliary Clearance1
2CompletedTreatmentChronic Rhinitis1
2CompletedTreatmentRespiratory Infections, Acute1
2CompletedTreatmentAcute Rhinitis1
2Enrolling by InvitationTreatmentAdenoid Hypertrophy1
2WithdrawnTreatmentHuman Immunodeficiency Virus (HIV) Infections / Sinusitis1
2, 3CompletedTreatmentAcute Upper Respiratory Tract Infections1
3CompletedNot AvailableUpper Respiratory Tract Infection1
3CompletedTreatmentAbortion in First Trimester1
3CompletedTreatmentCoughing1
3Unknown StatusTreatmentCoughing1
3Unknown StatusTreatmentViral Infections of the Upper Respiratory Tract1
4CompletedBasic ScienceHealthy Volunteers1
4CompletedPreventionAcute Upper Respiratory Track Infection1
4CompletedTreatmentAcute Rhinosinusitis / Respiratory Infections, Acute1
4CompletedTreatmentAcute maxillary sinusitis caused by M. catarrhalis / Bronchitis / Respiratory Infections, Acute1
4RecruitingOtherCYP2D6 Polymorphism1
Not AvailableCompletedNot AvailableBronchitis2
Not AvailableCompletedTreatmentBronchiolitis / Infections, Respiratory Syncytial Virus1
Not AvailableCompletedTreatmentFilamentary Keratitis1
Not AvailableCompletedTreatmentInfection NOS1
Not AvailableCompletedTreatmentPneumonia1
Not AvailableCompletedTreatmentUpper Back Pain1

Pharmacoeconomics

Manufacturers
  • Reckitt benckiser inc
Packagers
  • Adams Labs
  • Advanced Pharmaceutical Services Inc.
  • Alba Pharmacal
  • Aligon Pharmaceuticals Inc.
  • Allegis Pharmaceuticals
  • Ambi Pharmaceuticals Inc.
  • Amend
  • Amerisource Health Services Corp.
  • Anip Acquisition Co.
  • A-S Medication Solutions LLC
  • Atlantic Biologicals Corporation
  • Baroli
  • Bayer Healthcare
  • Bio Pharm Inc.
  • Boca Pharmacal
  • Bradley Pharmaceuticals Inc.
  • Breckenridge Pharmaceuticals
  • Brighton Pharmaceuticals
  • Bryant Ranch Prepack
  • BTA Pharmaceuticals
  • Capellon Pharmaceuticals LLC
  • Caraco Pharmaceutical Labs
  • Cardinal Health
  • Carwin Associates Inc.
  • Centurion Labs
  • Century Pharmaceuticals Inc.
  • Chemins Co. Inc.
  • Co Med Pharmaceuticals Inc.
  • Contract Pharm
  • CVS Pharmacy
  • Cypress Pharmaceutical Inc.
  • Dartmouth Pharmaceuticals Inc.
  • Deliz Pharmaceutical Corp.
  • Deltex Pharmaceuticals Inc.
  • Dental Essentials Inc.
  • Deston Therapeutics
  • Direct Dispensing Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Duramed
  • Econolab Inc.
  • Elge Inc.
  • Emrex Economed Pharmaceuticals Inc.
  • Ethex Corp.
  • Everett Laboratories Inc.
  • Generics Puerto Rico Inc.
  • Gm Pharmaceuticals Inc.
  • Great Southern Laboratories
  • Hawthorn Pharmaceuticals
  • Health Care Products
  • Heartland Repack Services LLC
  • Hi Tech Pharmacal Co. Inc.
  • Iopharm Laboratories Inc.
  • Ivax Pharmaceuticals
  • Jaymac Pharmaceuticals LLC
  • Kaiser Foundation Hospital
  • Kiel Laboratories Inc.
  • KV Pharmaceutical Co.
  • Kylemore Pharmaceuticals
  • Lark Pharmaceuticals Inc.
  • Larken Laboratories Inc.
  • Liberty Pharmaceuticals
  • Llorens Pharmaceutical
  • Major Pharmaceuticals
  • Marnel Pharmaceuticals Inc.
  • MCR American Pharmaceuticals Inc.
  • Meda AB
  • Murfreesboro Pharmaceutical Nursing Supply
  • Neilgen Pharma Inc.
  • Nexgen Pharma Inc.
  • Norega Laboratories Inc.
  • Nucare Pharmaceuticals Inc.
  • Pack Pharmaceuticals
  • Palmetto Pharmaceuticals Inc.
  • Pamlab LLC
  • Patheon Inc.
  • PCA LLC
  • PD-Rx Pharmaceuticals Inc.
  • Pegasus Laboratories Inc.
  • Pharma Medica Research Inc.
  • Pharmaceutical Association
  • Pharmaceutical Packaging Center
  • Pharmaceutical Utilization Management Program VA Inc.
  • Pharmedix
  • Physicians Total Care Inc.
  • Poly Pharmaceuticals Inc.
  • Portal Inc.
  • Prasco Labs
  • PRD Health Care
  • Preferred Pharmaceuticals Inc.
  • Prepak Systems Inc.
  • Provident Pharmaceuticals LLC
  • Qualitest
  • Quality Care
  • RA McNeil Co.
  • Rebel Distributors Corp.
  • Reckitt Benckiser Inc.
  • Remedy Repack
  • Resource Optimization and Innovation LLC
  • Respa Pharmaceuticals Inc.
  • Rij Pharmaceutical Corp.
  • River's Edge Pharmaceuticals
  • Sage Pharmaceuticals Inc.
  • Savage Labs
  • Scientific Laboratories Inc.
  • Scot-Tussin Lab
  • Seatrace Pharmaceuticals Inc.
  • Select Brand
  • Seyer Pharmatec Inc.
  • Silarx Pharmaceuticals
  • SJ Pharmaceuticals LLC
  • Southwood Pharmaceuticals
  • Stewart Jackson Pharmacal Inc.
  • Superior Pharmeceuticals
  • Teamm Pharmaceuticals Inc.
  • Teral Laboratories
  • Teva Pharmaceutical Industries Ltd.
  • TG United Inc.
  • Tri Med Laboratories Inc.
  • Unigen Pharmaceuticals
  • United Research Laboratories Inc.
  • Vindex Pharmaceuticals Inc.
  • Vintage Pharmaceuticals Inc.
  • Walgreen Co.
  • Weeks & Leo Co.
  • Wockhardt Ltd.
  • Wyeth Pharmaceuticals
  • Zyber Pharmaceuticals
Dosage forms
FormRouteStrength
TabletOral
Suspension / dropsOral
Tablet, multilayerOral
LiquidOral100 mg/5mL
LiquidOral100 mg
SyrupOral100 mg
SolutionOral100 mg/5mL
SolutionOral
Tablet, coatedOral
Capsule; kitOral
Capsule, liquid filledOral
SuppositoryRectal
Tablet, film coatedOral
KitOral97.5 mg/1
CapsuleOral
LiquidOral200 mg/5mL
KitOral
TabletOral100 mg/1
GranuleOral
SyrupOral
Kit; tabletOral
Solution / dropsNasal
Solution / dropsOral
SyrupOral200 mg/10mL
SolutionOral300 mg/15mL
TabletOral1000 mg/1
TabletOral1200 mg/1
TabletOral200 mg/1
TabletOral600 mg/1
SyrupOral100 mg/5mL
SolutionOral200 mg/10mL
ElixirOral
GelOral
Tablet, orally disintegratingOral100 mg/1
LiquidOral
LiquidOral5 g/100mL
SyrupOral50 mg/5mL
GranuleOral100 mg/1
Tablet, extended releaseOral600 mg/1
Tablet, multilayer, extended releaseOral
Tablet, extended releaseOral
Powder, for solutionOral
GranuleOral50 mg/1
SolutionOral
Tablet, extended releaseOral1200 mg/1
TabletOral400 mg
Tablet, coatedOral400 mg/1
Tablet, film coatedOral400 mg/1
Capsule, coatedOral
LiquidOral
TabletOral
SyrupOral
SyrupOral200 mg/5mL
TabletOral400 mg/1
LiquidOral200 mg/10mL
TabletOral750 mg/1
Capsule, gelatin coatedOral
LiquidOral100 mg/6.25mL
LiquidOral200 mg
LiquidOral200 mg/15mL
SuspensionOral
Prices
Unit descriptionCostUnit
Diabetic Tussin Max St 10-200 mg/5ml Liquid 118ml Bottle15.99USD bottle
Naldecon Senior EX 200 mg/5ml Syrup 118ml Bottle15.99USD bottle
P-ephed w/guaifen tablet1.21USD tablet
P-ephedrine-guaifen la tablet1.14USD tablet
Guaifen/p-ephed tablet sa1.01USD tablet
Organidin nr 200 mg tablet0.89USD tablet
Mucinex dm er 1200-60 mg tablet0.8USD tablet
Pseudoephedrine-guaifen tr tablet0.76USD tablet
Humibid e 400 mg tablet0.74USD tablet
Mucinex d er tablet0.73USD tablet
P-ephed w/guaifen tablet sr0.67USD tablet
Pseudoephedrine-guaif sr tablet0.63USD tablet
Guaifenesin/p-ephedrine tablet0.62USD tablet
P-ephed-guaifen tablet la0.6USD tablet
Kid's mucinex mini-melts pack0.57USD each
Mucinex cough mini-melt pack0.57USD each
Mucinex d tablet0.54USD tablet
Organidin NR 100 mg/5ml Liquid0.49USD ml
Codeine 10 mg-guai 300 mg liq0.46USD ml
Mucinex er 600 mg tablet0.44USD tablet
Mucinex 600 mg tablet0.42USD tablet
Mucinex full force nasal spray0.42USD ml
Mucinex moisture smart nas spr0.42USD ml
Tussi-Organidin NR 300-10 mg/5ml Liquid0.39USD ml
Mucus relief 400 mg tablet0.37USD tablet
Codeine-guaifen 10 mg-200 mg liq0.28USD ml
Guaifenesin 200 mg tablet0.28USD tablet
Guaifenesin-dm 400-20 mg tablet0.25USD tablet
Robitussin coughgels0.25USD each
Diabetic tussin ex 400 tablet0.2USD tablet
G-fenesin dm 20-400 mg caplet0.2USD caplet
Organ-i nr 200 mg tablet0.2USD tablet
G-fenesin 400 mg caplet0.19USD caplet
Guaifenesin 400 mg tablet0.16USD tablet
Chest congestion relief tablet0.15USD tablet
Guaifen p-ephed caplet er0.15USD caplet
Fenesin dm ir tablet0.13USD tablet
Fenesin pe ir tablet0.13USD tablet
Guaifenesin nr liquid0.13USD ml
Fenesin ir 400 mg tablet0.1USD tablet
Guaifenesin-dm nr liquid0.1USD ml
Guaifenesin-DM 100-10 mg/5ml Liquid0.09USD ml
Robitussin dm to go liquid0.09USD ml
Guaiacol liquid purified0.08USD ml
Guaifenesin dac oral solution0.08USD ml
Guaifenesin nr 100 mg/5 ml0.08USD ml
Children's mucinex cough liq0.06USD ml
Mucinex cold liquid0.06USD ml
Naldecon-dx senior0.06USD ml
Child's mucinex 100 mg/5 ml lq0.05USD ml
Guiatuss-dm syrup0.05USD ml
Adlt robitussin cough-cold-flu0.04USD ml
Adt robitussin cough-cold d lq0.04USD ml
Adult robitussin cough syrup0.04USD ml
Guiatuss DAC 30-10-100 mg/5ml Solution0.04USD ml
Robitussin chest congest syrup0.04USD ml
Robitussin cough & cold liquid0.04USD ml
Robitussin cough-cold liquid0.04USD ml
Robitussin cough-cong syrup0.04USD ml
Robitussin dm max liquid0.04USD ml
Robitussin long-acting liq0.04USD ml
Robitussin pe head & chest liq0.04USD ml
Robitussin-cough-chest-cong lq0.04USD ml
Robitussin-dm cough syrup0.04USD ml
Scot-tussin 100 mg/5 ml liq0.04USD ml
Guiatuss ac syrup0.03USD ml
Guiatuss-dac syrup0.03USD ml
Sb cough control syrup0.03USD ml
Guaifenesin ac cough syrup0.02USD ml
Guaifenesin dm syrup0.02USD ml
Guiatuss dm syrup0.02USD ml
Guiatuss-pe syrup0.02USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6372252No2002-04-162020-04-28Us
US6955821No2005-10-182020-04-28Us
US7838032No2010-11-232020-04-28Us
US9549907No2017-01-242035-11-13Us
US9808431No2017-11-072035-11-13Us
US10105324No2018-10-232035-11-13Us
Additional Data Available
  • Filed On
    Filed On

    The date on which a patent was filed with the relevant government.

    Learn more

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)78.5-79British Patent 628,497.
boiling point (°C)215 °C at 1.90E+01 mm HgPhysProp
water solubility5E+004 mg/L (at 25 °C)MERCK INDEX (1996)
logP1.39SMITH,JT & VINJAMOORI,DT (1995)
Predicted Properties
PropertyValueSource
Water Solubility14.9 mg/mLALOGPS
logP0.76ALOGPS
logP0.34ChemAxon
logS-1.1ALOGPS
pKa (Strongest Acidic)13.62ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area58.92 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity51.24 m3·mol-1ChemAxon
Polarizability20.59 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9231
Blood Brain Barrier-0.8631
Caco-2 permeable-0.6755
P-glycoprotein substrateSubstrate0.5523
P-glycoprotein inhibitor INon-inhibitor0.7979
P-glycoprotein inhibitor IINon-inhibitor0.9002
Renal organic cation transporterNon-inhibitor0.88
CYP450 2C9 substrateNon-substrate0.8348
CYP450 2D6 substrateNon-substrate0.8535
CYP450 3A4 substrateNon-substrate0.6853
CYP450 1A2 substrateInhibitor0.6013
CYP450 2C9 inhibitorNon-inhibitor0.9592
CYP450 2D6 inhibitorNon-inhibitor0.9616
CYP450 2C19 inhibitorNon-inhibitor0.9328
CYP450 3A4 inhibitorNon-inhibitor0.9481
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9445
Ames testNon AMES toxic0.7677
CarcinogenicityNon-carcinogens0.9215
BiodegradationReady biodegradable0.7769
Rat acute toxicity2.0868 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9171
hERG inhibition (predictor II)Non-inhibitor0.8735
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (7.98 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-00di-3900000000-022756bf476e39b7c0be
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0hb9-2900000000-261d308d57fa6814ad4e
1H NMR Spectrum1D NMRNot Applicable
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as anisoles. These are organic compounds containing a methoxybenzene or a derivative thereof.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Phenol ethers
Sub Class
Anisoles
Direct Parent
Anisoles
Alternative Parents
Phenoxy compounds / Methoxybenzenes / Alkyl aryl ethers / Secondary alcohols / 1,2-diols / Primary alcohols / Hydrocarbon derivatives
Substituents
Phenoxy compound / Methoxybenzene / Anisole / Alkyl aryl ether / Monocyclic benzene moiety / Secondary alcohol / 1,2-diol / Ether / Organic oxygen compound / Hydrocarbon derivative
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein group
Organism
Humans
Pharmacological action
Unknown
Actions
Antagonist
General Function
Voltage-gated cation channel activity
Specific Function
NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine. This protein plays a key role in synaptic p...

Components:
References
  1. Keshavarz M, Showraki A, Emamghoreishi M: Anticonvulsant Effect of Guaifenesin against Pentylenetetrazol-Induced Seizure in Mice. Iran J Med Sci. 2013 Jun;38(2):116-21. [PubMed:23825891]

Drug created on June 13, 2005 07:24 / Updated on December 07, 2019 14:26